2021
Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut, December 2020–February 2021
Britton A, Slifka K, Edens C, Nanduri SA, Bart S, Shang N, Harizaj A, Armstrong J, Xu K, Ehrlich HY, Soda E, Derado G, Verani JR, Schrag SJ, Jernigan JA, Leung VH, Parikh S. Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut, December 2020–February 2021. MMWR Morbidity And Mortality Weekly Report 2021, 70: 396-401. PMID: 33735160, PMCID: PMC7976620, DOI: 10.15585/mmwr.mm7011e3.Peer-Reviewed Original ResearchConceptsPfizer-BioNTech COVID-19 vaccineSkilled nursing facilitiesCOVID-19 vaccineLong-term care facilitiesSNF residentsNursing facilitiesCOVID-19 vaccine clinical trialsCOVID-19-associated morbidityEarly COVID-19 vaccinationSARS-CoV-2 infectionElectronic chart reviewVaccine effectiveness dataUnderlying medical conditionsVaccine clinical trialsCOVID-19 vaccinationPfizer-BioNTech vaccineSARS-CoV-2Long-term care programsStaff membersChart reviewFirst doseVaccination statusPartial vaccinationVaccine impactSecond dose
2020
Bordetella bronchiseptica: a rare cause of meningitis
Radcliffe C, Lier A, Doilicho N, Parikh S, Kaddouh F. Bordetella bronchiseptica: a rare cause of meningitis. BMC Infectious Diseases 2020, 20: 922. PMID: 33272197, PMCID: PMC7713019, DOI: 10.1186/s12879-020-05668-2.Peer-Reviewed Original ResearchConceptsRare causeBaseline neurological statusSetting of immunosuppressionOnset of symptomsCerebrospinal fluid leakTraumatic cerebrospinal fluid (CSF) leakHospital courseMechanical fallNeurological statusRecent surgeryRespiratory infectionsUlcerative colitisUnusual causeCase presentationWeDrain placementClinical conditionsFluid leakMeningitisAnimal contactMonoclonal antibodiesAnimal exposureAerobic coccobacillusB. bronchisepticaSystematic literature reviewCauseQuantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis
Pfeffer DA, Ley B, Howes RE, Adu P, Alam MS, Bansil P, Boum Y, Brito M, Charoenkwan P, Clements A, Cui L, Deng Z, Egesie OJ, Espino FE, von Fricken ME, Hamid MMA, He Y, Henriques G, Khan WA, Khim N, Kim S, Lacerda M, Lon C, Mekuria AH, Menard D, Monteiro W, Nosten F, Oo NN, Pal S, Palasuwan D, Parikh S, Pasaribu A, Poespoprodjo JR, Price DJ, Roca-Feltrer A, Roh ME, Saunders DL, Spring MD, Sutanto I, Ley-Thriemer K, Weppelmann TA, von Seidlein L, Satyagraha AW, Bancone G, Domingo GJ, Price RN. Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis. PLOS Medicine 2020, 17: e1003084. PMID: 32407380, PMCID: PMC7224463, DOI: 10.1371/journal.pmed.1003084.Peer-Reviewed Original ResearchConceptsG6PD activity measurementsG6PD activityDiagnostic Accuracy Studies-2 toolDormant liver stagesRisk of biasGlucose-6-phosphate dehydrogenase deficiencyStudy-level heterogeneityNormal control samplesReference diagnostic methodInter-study variabilityGlucose-6-phosphate dehydrogenase activityMalaria patientsHaematological conditionsLiver stagesRadical cureP. ovalePlasmodium vivaxPubMed searchIntermediate deficiencySystematic reviewDiagnostic thresholdMale medianStudy participantsMedian activityDiagnostic implicationsAn Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment
Francis J, Barnes KI, Workman L, Kredo T, Vestergaard LS, Hoglund RM, Byakika-Kibwika P, Lamorde M, Walimbwa SI, Chijioke-Nwauche I, Sutherland CJ, Merry C, Scarsi KK, Nyagonde N, Lemnge MM, Khoo SH, Bygbjerg IC, Parikh S, Aweeka FT, Tarning J, Denti P. An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. Antimicrobial Agents And Chemotherapy 2020, 64: 10.1128/aac.02394-19. PMID: 32071050, PMCID: PMC7179577, DOI: 10.1128/aac.02394-19.Peer-Reviewed Original ResearchConceptsDrug-drug interactionsAntiretroviral therapyDolutegravir-based antiretroviral therapyPotential drug-drug interactionsDay 7 concentrationsIndividual participant dataConcomitant efavirenzLopinavir-ritonavirLumefantrine exposureLumefantrine regimenAntituberculosis treatmentUncomplicated malariaAntiretroviral treatmentHIV infectionTreatment failurePopulation pharmacokineticsLumefantrine concentrationsLarger body weightBody weightEfavirenzParticipant dataLumefantrineMalariaAdult participantsRifampin